You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Access Language Arts

    SBC: ATTAINMENT CO., INC.            Topic: N/A

    Purpose: Instruction in English Language Arts (ELA) for students with severe intellectual disabilities and autism can be challenging, as these students often do not have the skills to engage with text. In recent years, special education experts have proposed a comprehensive approach to supporting students with intellectual disabilities and autism in ELA, centered on strategies including word ident ...

    SBIR Phase II 2014 Department of Education
  2. Antifungal Compound Discovery from Metagenomes

    SBC: LUCIGEN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antifungal compounds withpotentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial life. ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-retroviral therapy (ARV) consists of a cocktail of drugsthat blocks viral binding and replication, but does not destroy the HIV-1 provirus. In addition, ARV does not impact the large reservoir of laten ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel system for sensitive detection of botulinum neurotoxins

    SBC: ALPHA UNIVERSE LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The existence of terrorist organizations around the world, along with their ability to recruit expertise from physicians and scientists, poses an increasing threat of bioterrorist attack to society. In order to reduce the consequences of such an attack or even prevent it, new systems for detection of biothreat agents are necessary. Currently existing express ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. BAC Sudoku Sequencing Paradigm to Accelerate Metagenomic Natural Product Chemistr

    SBC: LUCIGEN CORPORATION            Topic: NCCIH

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against microbial pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antimicrobial compounds with potentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Increased bioavailability of polyphenols through bacterial metabolism

    SBC: AGRO BIOSCIENCES, INC.            Topic: NCCIH

    DESCRIPTION (provided by applicant): Numerous preclinical studies have demonstrated multiple health benefits including anti- inflammatory, antioxidant, and chemopreventive effects of dietary polyphenols. These compounds are abundant in plants and have added to the health benefits of many fruits, such as raspberries, pomegranates, and strawberries. As aging population in the U.S. and other develope ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Synergy between MAG-1 and Cyclophosphamide for Treatment of Recurrent SCLC

    SBC: Woomera Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, MAG-1, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that a cancer -specific provasopressin antigen, called GRSA, present at the surface of these tumors will prov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment

    SBC: CENTROSE LLC            Topic: NCI

    Project Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cases and 13,680 deaths will be attributed to renal cancerin the United States. Renal cancer is the most common malignancy of the adult kidney and accounts for 2-3% of all adult malignancies. Of these, 3 ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Dampening CAR therapy-induced cytokine storm with anti-GM-CSF antibodies

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term aim of this project is to reduce or eliminate the serious adverse events associated with cellular immunotherapy used to treat cancer. The current impressive efficacy of chimeric antigen receptor (CAR) T cell therapies is often accompanied by a well-known toxicity stemming from the large release of cytokines from activated immune cells, known as a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government